NCT00248430View on ClinicalTrials.gov

Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2003

Study Completion Date

July 31, 2007

Conditions

Graft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

therapeutic allogeneic lymphocytes

DRUG

melphalan

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (2)

98109-1023

Seattle Cancer Care Alliance, Seattle

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors

lead

Fred Hutchinson Cancer Center

OTHER

NCT00248430 - Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | Biotech Hunter | Biotech Hunter